Bitcoin price today: little changed near $119k ahead of Fed meet, tariff deadline
Daniel LeSueur, Chief Operating Officer of Health Catalyst , Inc. (NASDAQ:HCAT), executed a sale of 16,902 shares of the company’s common stock, according to a recent SEC filing. The healthcare technology company, currently valued at $277 million, has seen its stock decline over 45% in the past six months. The shares were sold at an average price of $4.5161 per share, totaling approximately $76,331. Following this transaction, LeSueur holds 216,250 shares directly. The sale was conducted under a pre-arranged trading plan established in March 2024, in line with Rule 10b5-1. According to InvestingPro analysis, HCAT is currently trading near its 52-week low of $3.76 and appears undervalued based on its Fair Value assessment. For deeper insights into insider trading patterns and 8 additional ProTips, consider exploring the comprehensive Pro Research Report available on InvestingPro.
In other recent news, Health Catalyst Inc. reported its financial results for the fourth quarter of 2024, revealing a notable earnings miss. The company posted an earnings per share (EPS) of -$0.33, which fell significantly short of the expected $0.07. Revenue for the quarter was $79.6 million, slightly below the anticipated $80.68 million. Despite this, Health Catalyst achieved a 6% year-over-year revenue increase, driven by a 10% growth in technology revenue, while professional services revenue remained flat. For the full year 2024, the company reported a total revenue of $370 million, marking a 4% increase from the previous year, with adjusted EBITDA surging by 137% to $26 million.
In other developments, Health Catalyst reaffirmed its revenue guidance for fiscal year 2025 at approximately $335 million, slightly below the consensus estimate of $336.8 million, while raising its EBITDA guidance to $41 million from the previously guided $39 million. The first-quarter EBITDA guidance for 2025 is set at around $4 million, notably lower than the consensus estimate of approximately $8.8 million. Analyst firm BTIG adjusted its price target for Health Catalyst shares from $13 to $10 but maintained a Buy rating on the stock. The company is phasing out lower-margin ambulatory Technology-Enabled Management Services (TEMS) agreements, which is expected to improve gross margins over time.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.